Dr. Hila Magen is a hematologist and multiple myeloma specialist at Sheba Medical Center in Israel, with extensive experience in the treatment of plasma cell disorders and advanced therapies for multiple myeloma. Her clinical work focuses on caring for patients with newly diagnosed and relapsed myeloma, including the use of innovative immunotherapy approaches such as CAR-T therapy, bispecific antibodies, and stem cell transplantation.
Dr. Magen is involved in both patient care and clinical research, with a particular interest in improving treatment outcomes and expanding access to advanced myeloma therapies. She regularly participates in international hematology and myeloma conferences, where specialists discuss the latest developments in myeloma treatment, personalized medicine, and emerging cellular therapies.
At Sheba Medical Center, Dr. Magen works as part of a multidisciplinary team treating Israeli and international patients with complex hematologic conditions. Her approach combines advanced medical expertise with close attention to the individual needs of each patient throughout the treatment process.
Research and Academic Activity
Dr. Hila Magen is actively involved in clinical and translational research in the field of hematologic malignancies, with a particular focus on advanced therapies for multiple myeloma and lymphoma. Her research interests include CAR-T cell therapy, innovative drug combinations for relapsed and refractory myeloma, and the development of more personalized treatment approaches for patients with complex blood cancers.
She has contributed to scientific publications indexed in PubMed and has co-authored articles published in leading international peer-reviewed journals, including Blood Advances, Leukemia & Lymphoma, and The Lancet Haematology.
Dr. Magen is also a member of several professional hematology organizations, including the Israeli Society of Hematology and Transfusion Medicine, the European Hematology Association (EHA), and the American Society of Hematology (ASH).
